A Phase 2, Open-label, Multiple Cohort, Single-arm, Multi-center Trial to Determine the Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-cell Acute Lymphoblastic Leukemia.
Latest Information Update: 05 Nov 2021
At a glance
- Drugs JCAR 015 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms ORBIT
- Sponsors Celgene Corporation
- 01 Mar 2017 According to a Juno Therapeutics media release, the company has made a strategic decision to cease development of JCAR015.
- 01 Mar 2017 According to a Juno Therapeutics media release, status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Nov 2016 New trial record